Financial Results, Limited Review Report for December 31, 2015
Orchid Pharma Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20152. Standalone Limited Review for the period ended December 31, 2015 Shareholding for the Period Ended December 31, 2015
Orchid Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
K Raghavendra Rao has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Orchid Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Change in Directorate
Orchid Pharma Ltd has informed BSE that Industrial Development Bank of India has withdrawn the nomination of Shri Nagaraj Garla and instead appointed Shri Rabinarayan Panda, Chief General Manager, IDBI Bank Ltd, Chennai as its nominee. He was appointed as a Nominee Director of Orchid Pharma Limited at the Board meeting held on December 30, 2015. Orchid Pharma gets inspection report
Chennai-based Orchid Pharma Ltd has informed the BSE that the company has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) based... Updates
Orchid Pharma Ltd has informed BSE that Orchid received the Establishment Inspection Report (EIR) from USFDA based on the successful inspection closure for the formulation manufacturing facility located at Irungattukottai, Sriperumbudur, Kancheepuram District, India. The facility was inspected by USFDA in the month of May 2015.
Orchid Pharma signs pact for $800 million loan from UK firm
The funding will help Orchid Pharma explore new growth opportunities while enabling the current business achieve incremental value Updates on Subsidiary Company
Orchid Pharma Ltd has informed BSE that Orchid Europe Limited, UK a wholly-owned subsidiary of Orchid Pharma Limited, India has entered into a long term financial arrangement to avail up to US$ 800 million (US Dollar Eight Hundred Million) as loan with Line Trust International, Guernsey, UK. This funding will help the Company explore new growth opportunities while enabling the current business achieve incremental value. Orchid Pharma changes trading name
Chennai-based Orchid Chemicals and Pharmaceuticals Ltd has informed the Bombay Stock Exchange that the company has changed the current trading symbol, ORCHIDCHEM, to ORCHIDPHAR which will be effec...